Terns Pharmaceuticals, Inc. - Common Stock (TERN)
CUSIP: 880881107
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 114,892,214
- Total 13F shares
- 65,586,958
- Share change
- +2,327,843
- Total reported value
- $446,681,549
- Put/Call ratio
- 26%
- Price per share
- $6.81
- Number of holders
- 124
- Value change
- +$17,184,836
- Number of buys
- 82
- Number of sells
- 49
Quarterly Holders Quick Answers
What is CUSIP 880881107?
CUSIP 880881107 identifies TERN - Terns Pharmaceuticals, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 880881107:
Top shareholders of TERN - Terns Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
|
Company |
6.6%
|
7,619,135
|
$49,981,526 | — | 31 Mar 2024 | |
| Vivo Capital, LLC |
13F
|
Company |
5.8%
|
6,657,992
|
$43,676,428 | — | 31 Mar 2024 | |
| Deep Track Capital, LP |
13F
|
Company |
5.3%
|
6,100,000
|
$40,016,000 | — | 31 Mar 2024 | |
| Vivo Opportunity, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
6,237,329
|
$38,671,440 | — | 01 Apr 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
3%
|
3,432,792
|
$22,519,116 | — | 31 Mar 2024 | |
| VR Adviser, LLC |
13F
|
Company |
3%
|
3,410,058
|
$22,369,980 | — | 31 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
2.9%
|
3,315,529
|
$21,749,871 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
2.6%
|
2,965,586
|
$19,454,245 | — | 31 Mar 2024 | |
| FMR LLC |
13F
|
Company |
2.4%
|
2,762,126
|
$18,119,547 | — | 31 Mar 2024 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
2.1%
|
2,381,896
|
$15,625,237 | — | 31 Mar 2024 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
1.9%
|
2,221,200
|
$14,571,072 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.9%
|
2,199,006
|
$14,425,479 | — | 31 Mar 2024 | |
| Fairmount Funds Management LLC |
13F
|
Company |
1.8%
|
2,040,000
|
$13,382,400 | — | 31 Mar 2024 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
1.7%
|
2,003,263
|
$13,131,390 | — | 31 Mar 2024 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.2%
|
1,363,675
|
$8,945,708 | — | 31 Mar 2024 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
1.1%
|
1,309,975
|
$8,593,436 | — | 31 Mar 2024 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
1%
|
1,195,794
|
$7,844,408 | — | 31 Mar 2024 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.94%
|
1,083,905
|
$7,110,417 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.79%
|
905,494
|
$5,940,041 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.75%
|
865,921
|
$5,681,197 | — | 31 Mar 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.74%
|
850,000
|
$5,576,000 | — | 31 Mar 2024 | |
| Russell Investments Group, Ltd. |
13F
|
Company |
0.55%
|
632,965
|
$4,152,249 | — | 31 Mar 2024 | |
| Octagon Capital Advisors LP |
13F
|
Company |
0.54%
|
625,000
|
$4,100,000 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.51%
|
586,793
|
$3,849,363 | — | 31 Mar 2024 | |
| ACUTA CAPITAL PARTNERS, LLC |
13F
|
Company |
0.4%
|
465,079
|
$3,050,918 | — | 31 Mar 2024 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.39%
|
450,000
|
$2,952,000 | — | 31 Mar 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.37%
|
421,637
|
$2,765,938 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.31%
|
355,796
|
$2,334,021 | — | 31 Mar 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.3%
|
340,017
|
$2,230,512 | — | 31 Mar 2024 | |
| LAV Biosciences Fund V, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
529,762
|
$2,002,500 | — | 23 Nov 2022 | |
| Monashee Investment Management LLC |
13F
|
Company |
0.26%
|
300,000
|
$1,968,000 | — | 31 Mar 2024 | |
| Eversept Partners, LP |
13F
|
Company |
0.25%
|
283,034
|
$1,856,703 | — | 31 Mar 2024 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.22%
|
250,551
|
$1,643,615 | — | 31 Mar 2024 | |
| BARCLAYS PLC |
13F
|
Company |
0.22%
|
248,304
|
$1,628,874 | — | 31 Mar 2024 | |
| BRIDGER MANAGEMENT, LLC |
13F
|
Company |
0.21%
|
246,800
|
$1,619,008 | — | 31 Mar 2024 | |
| Exome Asset Management LLC |
13F
|
Company |
0.2%
|
227,821
|
$1,494,506 | — | 31 Mar 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.18%
|
206,986
|
$1,357,829 | — | 31 Mar 2024 | |
| Samsara BioCapital, LLC |
13F
|
Company |
0.18%
|
202,348
|
$1,327,403 | — | 31 Mar 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.16%
|
186,009
|
$1,220,219 | — | 31 Mar 2024 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.15%
|
172,599
|
$1,132,249 | — | 31 Mar 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.14%
|
159,572
|
$1,046,793 | — | 31 Mar 2024 | |
| CITIGROUP INC |
13F
|
Company |
0.14%
|
157,561
|
$1,033,600 | — | 31 Mar 2024 | |
| HighVista Strategies LLC |
13F
|
Company |
0.13%
|
148,200
|
$972,192 | — | 31 Mar 2024 | |
| MYDA Advisors LLC |
13F
|
Company |
0.12%
|
140,000
|
$918,400 | — | 31 Mar 2024 | |
| NORGES BANK |
13F
|
Company |
0.12%
|
137,100
|
$899,376 | — | 31 Mar 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.1%
|
114,609
|
$751,835 | — | 31 Mar 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.1%
|
112,655
|
$739,017 | — | 31 Mar 2024 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.08%
|
88,497
|
$580,540 | — | 31 Mar 2024 | |
| PRELUDE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.07%
|
84,619
|
$555,101 | — | 31 Mar 2024 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.07%
|
74,755
|
$490,000 | — | 31 Mar 2024 |
Institutional Holders of Terns Pharmaceuticals, Inc. - Common Stock (TERN) as of Q2 2024
As of 30 Jun 2024,
Terns Pharmaceuticals, Inc. - Common Stock (TERN) was held by
124 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
65,586,958 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, Vivo Capital, LLC, Deep Track Capital, LP, Soleus Capital Management, L.P., BlackRock Inc., VR Adviser, LLC, FMR LLC, Point72 Asset Management, L.P., VANGUARD GROUP INC, and Schonfeld Strategic Advisors LLC.
This page lists
124
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
112
Q2 2024 holders
124
Holder diff
12
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.